{"id":13718,"date":"2025-10-22T20:52:49","date_gmt":"2025-10-22T18:52:49","guid":{"rendered":"https:\/\/www.kliinikum.ee\/yhendlabor\/?page_id=13718"},"modified":"2025-12-11T17:19:16","modified_gmt":"2025-12-11T15:19:16","slug":"haloperidool-p-haloperidol","status":"publish","type":"page","link":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/","title":{"rendered":"Haloperidool (P-Haloperidol)"},"content":{"rendered":"\n<p><em>Kliinilise keemia ja laboratoorse hematoloogia osakond<\/em><\/p>\n\n\n\n<p><strong>Haloperidool <\/strong>on but\u00fcrofenoonide r\u00fchma kuuluv antips\u00fchhootikum, mida kasutatakse skisofreenia, maniakaalse seisundi, luululise h\u00e4ire ja erineva geneesiga ps\u00fchhooside raviks. Preparaadi p\u00f5hiliseks toimeks on t\u00f5hus ps\u00fchhomotoorne sedatsioon.\u00a0<\/p>\n\n\n\n<p>Haloperidooli manustatakse suukaudselt tableti v\u00f5i lahusena ning intramuskulaarselt tava- v\u00f5i depoos\u00fcstena. Intramuskulaarsel manustamisel imendub ravim t\u00e4ielikult, maksimaalne plasmakontsentratsioon saavutatakse 20\u201340 minuti p\u00e4rast. Depoos\u00fcsti puhul vabaneb p\u00f5hiaine haloperidooldekanoaat j\u00e4rk-j\u00e4rgult lihaskoesse ning h\u00fcdrol\u00fc\u00fcsub aeglaselt vabaks haloperidooliks. Tableti v\u00f5i suukaudse lahuse kasutamisel imendub 60\u201370 % ravimi annusest ja maksimaalne plasmatase saabub tavaliselt 2\u20136 tunni jooksul.<\/p>\n\n\n\n<p>Ravim metaboliseerub ulatuslikult maksas. Intramuskulaarsel ja suukaudsel manustamisel on poolv\u00e4\u00e4rtusajad vastavalt 13\u201336 (kaskmiselt 21) ja 15\u201337 (keskmiselt 24) tundi. Lastel on eliminatsiooni poolv\u00e4\u00e4rtusajad l\u00fchemad. Haloperidooli keskmine seonduvus plasmavalkudega on t\u00e4iskasvanutel 88\u201392%, kuid see v\u00f5ib indiviiditi varieeruda.<\/p>\n\n\n\n<p>Haloperidooli koosmanustamine ts\u00fctokroom P450 ens\u00fc\u00fcme p\u00e4rssivate ravimitega suurendab antips\u00fchhootikumi plasmakontsentratsiooni ning sel juhul on vajalik ravimiannuse kohandamine. Tugevad CYP3A4 ens\u00fc\u00fcmi p\u00e4rssivad ravimid v\u00f5ivad v\u00e4hendada haloperidooli kontsentratsiooni, mis viib ravimi efektiivsuse v\u00e4henemiseni ning on vajalik ravimiannuse kohandamine. &nbsp;<\/p>\n\n\n\n<p>K\u00f5ige sagedasemateks k\u00f5rvaltoimeteks on ekstrap\u00fcramidaalh\u00e4ired, unetus, agiteeritus, h\u00fcperkineesia, peavalu, ps\u00fchhootiline h\u00e4ire. \u00dcleannustamise peamisteks s\u00fcmptomiteks on rasked ekstrap\u00fcramidaalsed reaktsioonid, h\u00fcpotensioon ja sedatsioon.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Uuritav materjal, selle v\u00f5tmine, saatmine ja s\u00e4ilitamine<\/strong><\/p>\n\n\n\n<p>Proov tuleb v\u00f5tta vahetult enne j\u00e4rgmise ravimiannuse manustamist!<\/p>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table width=\"100%\"><tbody><tr><td width=\"1%\"><\/td><td width=\"15%\"><strong>Katsuti<\/strong><\/td><td width=\"84%\">K2E\/K3E-katsuti (lilla kork)<\/td><\/tr><tr><td><\/td><td><strong>S\u00e4ilivus<\/strong><\/td><td>Plasmas +4 \u00b0C \u00fcks n\u00e4dal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Anal\u00fc\u00fcsi tegemise aeg<\/strong><strong>:<\/strong> \u00fcks kord n\u00e4dalas<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Anal\u00fc\u00fcsimeetod<\/strong><strong>:<\/strong> vedelikkromatograafia-massispektromeetria (LC-MS\/MS)<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>Referentsv\u00e4\u00e4rtused<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table width=\"100%\"><tbody><tr><td width=\"1%\"><\/td><td width=\"20%\"><strong>\u2265 18 a<\/strong><\/td><td width=\"59%\">Soovituslik terapeutiline vahemik*<\/td><td width=\"20%\">1\u201310 \u00b5g\/L<\/td><\/tr><tr><td><\/td><td>&nbsp;<\/td><td>Toksiline kontsentratsioon*<\/td><td>&gt;15 \u00b5g\/L<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>*C. Hiemke et al (2018). \u201eConsensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017\u201c Pharmacopsychiatry 2018; 51: 9\u201362<\/p>\n\n\n\n<p>Terapeutiline vahemik ja toksiline piir ei ole \u00fcheselt m\u00e4\u00e4ratud. Antud terapeutiline vahemik p\u00f5hineb populatsiooniuuringutel, seega ei pruugi olla rakendatav igale patsiendile. M\u00f5ne patsiendi puhul v\u00f5ib optimaalne ravivastus olla ravimikontsentratsiooni juures, mis j\u00e4\u00e4b antud vahemikust v\u00e4lja.<\/p>\n\n\n\n<p class=\"has-medium-font-size\"><strong>N\u00e4idustus ja kliiniline t\u00e4hendus<\/strong><\/p>\n\n\n\n<p>Ravi j\u00e4lgimine, optimaalse raviskeemi leidmine ja kontroll, ravimim\u00fcrgistuse diagnostika.<\/p>\n\n\n\n<p>Koostajad: Julia Keller, Jelena Beljantseva<br>03.06.2020<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kliinilise keemia ja laboratoorse hematoloogia osakond Haloperidool on but\u00fcrofenoonide r\u00fchma kuuluv antips\u00fchhootikum, mida kasutatakse skisofreenia, maniakaalse seisundi, luululise h\u00e4ire ja erineva geneesiga ps\u00fchhooside raviks. Preparaadi p\u00f5hiliseks toimeks on t\u00f5hus ps\u00fchhomotoorne sedatsioon.\u00a0 Haloperidooli manustatakse suukaudselt tableti v\u00f5i lahusena ning intramuskulaarselt tava- v\u00f5i depoos\u00fcstena. Intramuskulaarsel manustamisel imendub ravim t\u00e4ielikult, maksimaalne plasmakontsentratsioon saavutatakse 20\u201340 minuti p\u00e4rast. Depoos\u00fcsti puhul [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":0,"parent":7301,"menu_order":8,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-13718","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Haloperidool (P-Haloperidol) - \u00dchendlabor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haloperidool (P-Haloperidol) - \u00dchendlabor\" \/>\n<meta property=\"og:description\" content=\"Kliinilise keemia ja laboratoorse hematoloogia osakond Haloperidool on but\u00fcrofenoonide r\u00fchma kuuluv antips\u00fchhootikum, mida kasutatakse skisofreenia, maniakaalse seisundi, luululise h\u00e4ire ja erineva geneesiga ps\u00fchhooside raviks. Preparaadi p\u00f5hiliseks toimeks on t\u00f5hus ps\u00fchhomotoorne sedatsioon.\u00a0 Haloperidooli manustatakse suukaudselt tableti v\u00f5i lahusena ning intramuskulaarselt tava- v\u00f5i depoos\u00fcstena. Intramuskulaarsel manustamisel imendub ravim t\u00e4ielikult, maksimaalne plasmakontsentratsioon saavutatakse 20\u201340 minuti p\u00e4rast. Depoos\u00fcsti puhul [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00dchendlabor\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T15:19:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/haloperidool-p-haloperidol\\\/\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/haloperidool-p-haloperidol\\\/\",\"name\":\"Haloperidool (P-Haloperidol) - \u00dchendlabor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\"},\"datePublished\":\"2025-10-22T18:52:49+00:00\",\"dateModified\":\"2025-12-11T15:19:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/haloperidool-p-haloperidol\\\/#breadcrumb\"},\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/haloperidool-p-haloperidol\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/haloperidool-p-haloperidol\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00e4siraamat\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ravimiseire uuringud\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/ravimiseire-uuringud\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Haloperidool (P-Haloperidol)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\",\"name\":\"\u00dchendlabor\",\"description\":\"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Haloperidool (P-Haloperidol) - \u00dchendlabor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/","og_locale":"et_EE","og_type":"article","og_title":"Haloperidool (P-Haloperidol) - \u00dchendlabor","og_description":"Kliinilise keemia ja laboratoorse hematoloogia osakond Haloperidool on but\u00fcrofenoonide r\u00fchma kuuluv antips\u00fchhootikum, mida kasutatakse skisofreenia, maniakaalse seisundi, luululise h\u00e4ire ja erineva geneesiga ps\u00fchhooside raviks. Preparaadi p\u00f5hiliseks toimeks on t\u00f5hus ps\u00fchhomotoorne sedatsioon.\u00a0 Haloperidooli manustatakse suukaudselt tableti v\u00f5i lahusena ning intramuskulaarselt tava- v\u00f5i depoos\u00fcstena. Intramuskulaarsel manustamisel imendub ravim t\u00e4ielikult, maksimaalne plasmakontsentratsioon saavutatakse 20\u201340 minuti p\u00e4rast. Depoos\u00fcsti puhul [&hellip;]","og_url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/","og_site_name":"\u00dchendlabor","article_modified_time":"2025-12-11T15:19:16+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/","name":"Haloperidool (P-Haloperidol) - \u00dchendlabor","isPartOf":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website"},"datePublished":"2025-10-22T18:52:49+00:00","dateModified":"2025-12-11T15:19:16+00:00","breadcrumb":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/#breadcrumb"},"inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/haloperidool-p-haloperidol\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/"},{"@type":"ListItem","position":2,"name":"K\u00e4siraamat","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/"},{"@type":"ListItem","position":3,"name":"Ravimiseire uuringud","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/ravimiseire-uuringud\/"},{"@type":"ListItem","position":4,"name":"Haloperidool (P-Haloperidol)"}]},{"@type":"WebSite","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/","name":"\u00dchendlabor","description":"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kliinikum.ee\/yhendlabor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Kadi Siigur","author_link":"https:\/\/www.kliinikum.ee\/yhendlabor\/author\/kadisi\/"},"uagb_comment_info":0,"uagb_excerpt":"Kliinilise keemia ja laboratoorse hematoloogia osakond Haloperidool on but\u00fcrofenoonide r\u00fchma kuuluv antips\u00fchhootikum, mida kasutatakse skisofreenia, maniakaalse seisundi, luululise h\u00e4ire ja erineva geneesiga ps\u00fchhooside raviks. Preparaadi p\u00f5hiliseks toimeks on t\u00f5hus ps\u00fchhomotoorne sedatsioon.\u00a0 Haloperidooli manustatakse suukaudselt tableti v\u00f5i lahusena ning intramuskulaarselt tava- v\u00f5i depoos\u00fcstena. Intramuskulaarsel manustamisel imendub ravim t\u00e4ielikult, maksimaalne plasmakontsentratsioon saavutatakse 20\u201340 minuti p\u00e4rast. Depoos\u00fcsti puhul&hellip;","_links":{"self":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/13718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/comments?post=13718"}],"version-history":[{"count":0,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/13718\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/7301"}],"wp:attachment":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/media?parent=13718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}